



cancers



an Open Access Journal by MDPI

Autologous and Allogeneic Stem Cell Transplant in Cancer Therapy

Guest Editors:

Dr. Yvonne A. Efebera

Division of Hematology, Blood
and Marrow Transplant,
OhioHealth, Columbus, OH
43214, USA

Dr. Nidhi Sharma

Department of Internal Medicine,
Division of Hematology, The Ohio
State University, Columbus, OH
43210, USA

Deadline for manuscript
submissions:

closed (20 June 2022)

Message from the Guest Editors

Dear Colleagues,

This Special Issue is about the advances made in recent years in the field of hematopoietic stem cell transplantation (SCT). Over the past 10 to 20 years, there have been significant improvements in the field of both autologous and allogeneic transplantation. The upper age limit for hematopoietic stem cell transplantation continues to increase for both autologous SCT (ASCT) and allogeneic SCT (allo-SCT). Improvement in supportive management and development of novel agents has led to increases in survival outcomes in patients undergoing ASCT for multiple myeloma and lymphoma. Advances in conditioning regimens, the expanding use of alternative donor stem cell sources such as haploidentical stem cells and cord blood, and the use of modern T-cell depletion strategies such as post-transplant cyclophosphamide have led to better survival outcomes and reduction in incidences of graft versus host disease in patients undergoing allo-SCT. Further, the advent of adoptive immunotherapy in allo-SCT through the role of the graft-versus-leukemia (GVL) effect has further widened the scope of treatment.



mdpi.com/si/65233

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI